Bone morphogenetic protein-4 control of pituitary pathophysiology

Front Horm Res. 2006:35:22-31. doi: 10.1159/000094262.

Abstract

Bone morphogenetic protein-4 (BMP-4), a member of the transforming growth factor-Beta(TGF-Beta) family, is overexpressed in different prolactinoma models and induces the development of these lineage adenomas. SMAD proteins activated by growth factors of the TGF-Beta and BMP family interact with estrogen receptors to stimulate the proliferation of prolactin and growth hormone-secreting cells. Furthermore, BMP-4 presents differential expression in normal and adenomatous corticotropes and inhibitory action on corticotropinoma cell proliferation. Moreover, BMP-4 mediates the antiproliferative action of retinoic acid in these cells. The present review highlights not only the crucial and opposite role of BMP-4 in the progression of pituitary adenomas but also that BMP-4 and retinoic acid interaction might serve as a potential new mechanism target for therapeutic approaches for Cushing disease.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adrenocorticotropic Hormone / metabolism
  • Animals
  • Bone Morphogenetic Protein 4
  • Bone Morphogenetic Proteins / metabolism
  • Bone Morphogenetic Proteins / physiology*
  • Gene Expression
  • Humans
  • Models, Biological
  • Neurons / metabolism
  • Pituitary Diseases / etiology*
  • Pituitary Gland / cytology
  • Pituitary Gland / growth & development
  • Pituitary Gland / metabolism
  • Receptors, Transforming Growth Factor beta / metabolism
  • Transforming Growth Factor beta / physiology
  • Tretinoin / pharmacology

Substances

  • BMP4 protein, human
  • Bone Morphogenetic Protein 4
  • Bone Morphogenetic Proteins
  • Receptors, Transforming Growth Factor beta
  • Transforming Growth Factor beta
  • Tretinoin
  • Adrenocorticotropic Hormone